JP7820798B2 - 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 - Google Patents

赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法

Info

Publication number
JP7820798B2
JP7820798B2 JP2021569268A JP2021569268A JP7820798B2 JP 7820798 B2 JP7820798 B2 JP 7820798B2 JP 2021569268 A JP2021569268 A JP 2021569268A JP 2021569268 A JP2021569268 A JP 2021569268A JP 7820798 B2 JP7820798 B2 JP 7820798B2
Authority
JP
Japan
Prior art keywords
alkyl
abcg2
ppix
group
epp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532923A5 (https=
JP2022532923A (ja
Inventor
マ，シャオチャオ
ジュゥ，ジュンジー
ル，ジー
Original Assignee
ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション filed Critical ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Publication of JP2022532923A publication Critical patent/JP2022532923A/ja
Publication of JP2022532923A5 publication Critical patent/JP2022532923A5/ja
Priority to JP2025164289A priority Critical patent/JP2026027223A/ja
Application granted granted Critical
Publication of JP7820798B2 publication Critical patent/JP7820798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03044—Xenobiotic-transporting ATPase (3.6.3.44)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2021569268A 2019-05-20 2020-05-20 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法 Active JP7820798B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025164289A JP2026027223A (ja) 2019-05-20 2025-09-30 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962850061P 2019-05-20 2019-05-20
US62/850,061 2019-05-20
PCT/US2020/033746 WO2020236901A1 (en) 2019-05-20 2020-05-20 A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025164289A Division JP2026027223A (ja) 2019-05-20 2025-09-30 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法

Publications (3)

Publication Number Publication Date
JP2022532923A JP2022532923A (ja) 2022-07-20
JP2022532923A5 JP2022532923A5 (https=) 2023-05-26
JP7820798B2 true JP7820798B2 (ja) 2026-02-26

Family

ID=73458653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569268A Active JP7820798B2 (ja) 2019-05-20 2020-05-20 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法
JP2025164289A Pending JP2026027223A (ja) 2019-05-20 2025-09-30 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025164289A Pending JP2026027223A (ja) 2019-05-20 2025-09-30 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法

Country Status (6)

Country Link
US (1) US12528808B2 (https=)
EP (1) EP3972605A4 (https=)
JP (2) JP7820798B2 (https=)
CN (1) CN114096250B (https=)
CA (1) CA3135592A1 (https=)
WO (1) WO2020236901A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3135592A1 (en) 2019-05-20 2020-11-26 Xiaochao Ma Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
US11813257B2 (en) * 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CN120965522B (zh) * 2025-10-20 2026-02-17 兰树化妆品股份有限公司 一种Fmoc-Tea-OH及其制备方法和在多肽合成中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
US9114102B2 (en) 2007-11-07 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting ABCG2 and related treatments
WO2009088831A2 (en) 2008-01-03 2009-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of inhibiting abcg2 and other treatment methods
US9056111B1 (en) 2011-09-21 2015-06-16 Stc.Unm Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment
EP3054951A4 (en) * 2013-10-07 2017-05-10 Millennium Pharmaceuticals, Inc. Inhibitor of breast cancer resistance protein (bcrp)
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3341079A4 (en) 2015-08-25 2019-05-08 President and Fellows of Harvard College METHOD AND COMPOSITIONS RELATED TO DIAGNOSIS AND TREATMENT OF CANCER
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
CN106191061B (zh) 2016-07-18 2019-06-18 暨南大学 一种特异靶向人ABCG2基因的sgRNA导向序列及其应用
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
CA3135592A1 (en) 2019-05-20 2020-11-26 Xiaochao Ma Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2001年，vol.11, issue 1，p.29-32
Bioorg. Med. Chem. Lett.，2016年，vol.26, issue 2，p.551-555
Blood，2005年，vol.105, issue 6，p.2571-2576
Nat. Struct. Mol. Biol.，2018年，vol.25, no.4，p.333-340, Supplementary Information
Tetrahedron，2007年，vol.63, issue 25，p.5510-5528

Also Published As

Publication number Publication date
EP3972605A1 (en) 2022-03-30
JP2026027223A (ja) 2026-02-18
CA3135592A1 (en) 2020-11-26
US12528808B2 (en) 2026-01-20
WO2020236901A1 (en) 2020-11-26
CN114096250A (zh) 2022-02-25
CN114096250B (zh) 2025-01-14
US20220249473A1 (en) 2022-08-11
EP3972605A4 (en) 2023-10-04
JP2022532923A (ja) 2022-07-20

Similar Documents

Publication Publication Date Title
JP2026027223A (ja) 赤芽球増殖性プロトポルフィリン症（ｅｐｐ）およびｘ連鎖プロトポルフィリン症（ｘｌｐ）のための新規療法
CN107406416B (zh) 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
CA3153853A1 (en) Targeted bifunctional degraders
JP6830948B2 (ja) Ｍｉｄｈ１阻害剤としての縮合イミダゾール
WO2021260438A1 (en) Antibody-drug conjugates comprising anti-b7-h3 antibodies
BR112019028295A2 (pt) compostos que compreendem ligante clivável e usos dos mesmos
CN102573500A (zh) 巨噬细胞相关疾病的治疗
CN107921051A (zh) 抑制精氨酸酶活性的组合物和方法
CN113811333A (zh) 靶向抗癌核激素受体的化合物
JP2009539769A (ja) カペシタビン併用療法
WO2021195598A2 (en) Degrader-antibody conjugates and methods of using same
CN107708686B (zh) 氧杂二环庚烷前药
WO2023056069A1 (en) Degrader-antibody conjugates and methods of using same
CN107922420A (zh) 用于治疗社交障碍和药物使用障碍的治疗性化合物和组合物
JP2018522838A (ja) ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール
CN114746093A (zh) 治疗血管畸形的方法
WO2025129116A1 (en) Compounds for the targeted degradation of smarca2
TW202509035A (zh) Ｊａｋ抑制劑化合物及晶型
HK40041072A (en) Oxabicycloheptane prodrugs for use in treating cancer
EA051180B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие антитела к b7-h3
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合
HK1226065B (zh) 连接物关联激酶1的抑制剂、包含其的组合物、及其使用方法
HK1247576B (en) Oxabicycloheptane prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260205

R150 Certificate of patent or registration of utility model

Ref document number: 7820798

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150